Fundraising Fox
Resistell
Founded 2017 · 14 employees on LinkedIn · 3 known investors
Find your way into Resistell
Sign up to see every warm intro you have to Resistell
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Resistell team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Resistell develops a nanomotion-based diagnostic device for rapid phenotypic antibiotic susceptibility testing (AST), aimed at accelerating detection of antibiotic resistance in hospital settings. The Swiss company's IVD product is intended for clinical microbiology use with bacterial pathogens.
Founders & leadership
Resistell was founded in 2017 by Dr. Danuta Cichocka.
DD
Dr. Danuta CichockaCEO, Co-Founder, Board MemberDr. Cichocka is a microbiologist with 20 years of research and product development experience who co-founded and serves as CEO of Resistell, a Swiss diagnostics company that develops nanomotion-based antibiotic susceptibility testing devices for hospital microbiology labs.
DA
Dr. Alex SturmChief Scientific OfficerDr. Sturm is Chief Scientific Officer at Resistell, a Swiss diagnostics company developing nanomotion-based antibiotic susceptibility testing devices. He has over 15 years of experience in microbiology, infectious diseases, and in vitro diagnostic development, with expertise in bacterial physiology and clinical study management.
MB
Martin BirkCFOMartin Birk is a CFO and biotech entrepreneur with over 16 years of experience in life sciences, medtech, and regulated startups, including roles in fundraising, financial operations, and M&A strategy. He is co-founder and CEO of TransHeps AG, a company developing diagnostic tools for liver cell-based testing.
Investors · 3
Alpana Ventureslisted by Alpana VenturesGeneva
How we know: Alpana Ventures's portfolio page · Not right? Tell us
OCCIDENTlisted by OCCIDENTMunich
How we know: press coverage · Not right? Tell us
TRUMPF VenturereportedDitzingen · $540K – $4.3M
How we know: press coverage · Not right? Tell us
Frequently asked questions
- What does Resistell do?
- Resistell develops a nanomotion-based diagnostic device for rapid phenotypic antibiotic susceptibility testing (AST), aimed at accelerating detection of antibiotic resistance in hospital settings. The Swiss company's IVD product is intended for clinical microbiology use with bacterial pathogens.
- Who founded Resistell?
- Resistell was founded by Dr. Danuta Cichocka in 2017.
- Who are Resistell's investors?
- Resistell's investors include Alpana Ventures, OCCIDENT, TRUMPF Venture.